Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-11-10
2001-05-01
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06225325
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the field of cancer chemotherapy. More particularly, the present invention relates to a method for improving the effectiveness of cancer chemotherapy by preventing, reducing, or reversing the development of cellular resistance to chemotherapeutic agents, i.e., the phenomenon known as “multidrug resistance” (MDR), during the course of therapy. This is achieved by administering to patients N-alkyl-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compounds (“iminosugars”) in conjunction with chemotherapeutic drugs.
2. Description of Related Art
Multidrug Resistance (MDR)
Multidrug resistance, the phenomenon whereby primary exposure of tumor cells to a single chemotherapeutic drug results in cellular resistance to multiple drugs, is believed to be the basis for tumor cell survival (Bradley et al. (1988)
Biochim. Biophys. Acta
948:87-128). MDR is manifested as a simultaneously acquired cellular resistance to several cytotoxic substances, which can be surprisingly structurally and functionally unrelated, and is often observed after prolonged exposure of cells to anticancer drugs of the “multidrug resistance group.” The latter includes such different compounds as actinomycin D, mitomycin C, anthracyclines, colchicine, rhodamine, ethidium bromide, doxorubicin, epipodophyllotoxins, paclitaxel, taxol, reserpine, and the vinca alkaloids. Exposure of cells to one of these drugs can lead not only to specific resistance to this drug, but also to non-specific cross-resistance to all the other drugs of the MDR group.
Study of this phenomenon has focused on a number of different possible biological mechanisms. Volm et al. ((1993)
Cancer
71:2981-2987) and Bradley et al. ((1994)
Cancer Metastasis Rev.
13:223-233) have investigated the overexpression of P-gp, a plasma membrane glycoprotein believed to rapidly efflux MDR-type drugs, thus protecting cells from damage by preventing these drugs from reaching their intracellular targets. Doige et al. ((1993)
Biochim. Biophys. Acta
1146:65-72) and Wadkins et al. ((1993)
Biochim. Biophys. Acta
1153:225-236) have studied the role of lipids in MDR. While differences in the glycerolipid and sphingomyelin compositions of MDR and drug-sensitive cells have been observed (Holleran et al. (1986)
Cancer Chemother. Pharmacol.
17:11-15; Ramu et al. (1984)
Cancer Treat. Rep.
68:637-641; May et al. (1988)
Int. J. Cancer
42:728-733; Welsh et al. (1994)
Arch. Biochem. Biophys.
315:41-47; Wright et al. (1985)
Biochem. Biophys. Res. Commun.
133:539-545), and the ganglioside composition of MDR and drug-sensitive cells has been investigated, no clear picture as to the basis of drug resistance emerged from these studies.
More recently, Lavie et al. ((1996)
J. Biol. Chem.
271:19530-10536) demonstrated a correlation between the cellular content of glycosphingolipids and MDR. These workers demonstrated that tamoxifen, verapamil, and cyclosporin A, agents that reverse multidrug resistance, as well as 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, decrease glucosylceramide levels in an MDR human breast cancer cell line that accumulates high levels of glucosylceramide compared with the parental wild-type, drug-sensitive cell line (Lavie et al. (1997)
J. Biol. Chem.
272:1682-1687). They concluded that high cellular levels of glucosylceramide are correlated with MDR, and that glycolipids are therefore a target for the action of MDR-reversing agents.
1,5-dideoxy-1,5-imino-D-glucitol and galactitol Compounds
1,5-dideoxy-1,5-imino-D-glucitol (also known as 1-deoxynojirimycin, DNJ) and its N-alkyl derivatives are known inhibitors of the N-linked oligosaccharide processing enzymes &agr;-glucosidase I and II (Saunier et al.,
J. Biol.Chem. (
1982) 257:14155-14161 (1982); Elbein,
Ann. Rev. Biochem.
(1987) 56:497-534). As glucose analogs, they were also predicted to have the potential to inhibit glucose transport, glucosyltransferases, and/or glycolipid synthesis (Newbrun et al.,
Arch. Oral Biol.
(1983) 28: 516-536; Wang et al.,
Tetrahedron Lett.
(1993) 34:403-406). Their inhibitory activity against glucosidases has led to the development of these compounds as anti-hyperglycemic agents and antiviral agents. See, for example, PCT International Publication WO 87/03903 and U.S. Pat. Nos. 4,065,562; 4,182,767; 4,533,668; 4,639,436; 4,849,430; 4,957,926; 5,011,829; and 5,030,638. N-butyl DNJ is an inhibitor of HIV replication in vitro (Fleet et al. (1988)
FEBS Lett.
237:128-132; Karpas et al. (1988)
Proc. Natl. Acad. Sci. USA
85:9229-9233). This compound has been clinically evaluated as a potential AIDS therapeutic (Jacob et al. (1992) in
Natural Products as Antiviral Agents,
C. K. Chu et al., Eds., pp. 137-152, Plenum Publishing Co., N.Y.), and has been found to exhibit little cytotoxicity in vitro (Platt et al. (1992)
Eur. J. Biochem.
208:187-193).
Platt et al. ((1994) J. Biol. Chem. 269:8362-8365) have demonstrated that certain N-alkylated derivatives of DNJ inhibit the glucosyltransferase-catalyzed biosynthesis of glucosylceramide, resulting in the inhibition of biosynthesis of all glucosylceramide-based glycosphingolipids. Glycolipids constitute an important class of glycoconjugates found in the membranes, and particularly the plasma membrane, of eukaryotic cells. These authors speculated that these N-alkylated derivatives specifically inhibit UDP-glucose-N-acylsphingosine glucosyltransferase (EC 2.4.1.80). This transferase generates glucosylceramide (GlcCer), the precursor for the more complex glycosphingolipids and gangliosides. Platt et al. also demonstrated that N-butyl DNJ inhibited glycolipid expression at the cell surface. The authors suggested that N-alkylated DNJs would be useful in treating lysosomal glycolipid storage disorders such as Gaucher's disease.
In a subsequent paper, Platt et al. showed that the galactose analogue of N-butyl DNJ, i.e., N-butyl-deoxygalactonojirimycin (N-butyl DGJ), is a more selective inhibitor of glycolipid biosynthesis, only weakly inhibiting the N-linked oligosaccharide processing enzymes &agr;-glucosidases I and II, and not inhibiting lysosomal &bgr;-glucocerebrosidase (which is required for the cleavage of GlcCer to glucose and ceramide). N-butyl DGJ was shown to be comparable to N-butyl DNJ as an inhibitor of UDP-glucose-N-acylsphingosine glucosyltransferase and in preventing lysosomal glycolipid storage in an in vitro model of Gaucher's disease.
In 1997, Platt et al. (Science 276:428-431) reported the prevention of glycosphingolipid lysosomal storage in a mouse model of Tay-Sachs disease using N-butyl DNJ. This disease is characterized by a deficiency in the A isoenzyme of &bgr;-hexosaminidase, which degrades G
M2
ganglioside. A deficiency of this enzyme in humans results in accumulation of G
M2
ganglioside in brain cell lysosomes, leading to severe neurological degeneration. The authors noted that this compound is water soluble and noncytotoxic over a broad range of concentrations in vitro and in vivo. Oral administration to healthy mice resulted in glycosphingolipid depletion in multiple organs without causing any overt pathological side effects. In Tay-Sachs mice, no toxicity to N-butyl DNJ was observed based on visible inspection and observation of the animals, and of organ weights at autopsy. While spleen and thymus tissues were 50% acellular, no immunocompromization was apparent. The authors concluded that in this in vivo mammalian model, oral treatment with N-butyl DNJ is well tolerated, and effectively inhibits glycosphingolipid biosynthesis and subsequent accumulation in brain cell lysosomes.
Treatment of MDR
Many chemosensitizers have been reported to antagonize MDR in in vitro systems, and some have been shown to be effective in viva when coadministered with appropriate chemotherapeutic agents to nude mice bearing multidrug-resistant tumors. Unfortunately, success in the laboratory has not necessarily translated to success in the clinic. Dose-limiting s
G.D. Searle & Company
Jones Dwayne C.
Senniger Powers Leavitt & Roedel
LandOfFree
Use of alkylated iminosugars to treat multidrug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of alkylated iminosugars to treat multidrug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of alkylated iminosugars to treat multidrug resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2496264